Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug cocktail aims to crush myeloma early

NCT ID NCT02405364

Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested a three-drug combination (carfilzomib, lenalidomide, and dexamethasone) followed by a stem cell transplant and maintenance therapy in 46 newly diagnosed multiple myeloma patients aged 65 or younger. The goal was to see if this intensive approach could lead to deep remissions. The study is complete, but results are not yet widely available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
carfilzomib, lenalidomide, and dexamethasone (CRd) with stem cell transplant
What this could lead to
If successful, this combination could improve remission rates and delay disease progression in younger multiple myeloma patients.
What could go wrong
This is a small, early-phase trial (46 patients) with no control group, so results may not apply broadly. The intensive regimen carries risks like infection and bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

46 people

The number who actually took part.

Started

Feb 2014

Finished

Nov 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients diagnosed with multiple myeloma based on the new International Myeloma Working Group * Subjects must have symptomatic myeloma with at least one CRAB criteria * Subjects must not have been treated previously with any systemic therapy for multiple myeloma Exclusion Criteria: * Pregnant or lactating females * Evidence of mucosal or internal bleeding and/or platelet refractory * Acute active infection requiring treatment * Treatment by localized radiotherapy if the interval between the end of radiotherapy and initiation of protocol therapy lower than 2 weeks * Treatment by corticosteroids if exceed the equivalent of 160 mg of dexamethasone in a 2-week period before initiation therapy * Subjects not eligible for high dose therapy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple myeloma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple myeloma

Contacts and locations

Locations

  • CHRU Dijon

    Dijon, France

  • CHRU Hôtel Dieu

    Nantes, France

  • CHU Grenoble

    Grenoble, France

  • CHU Henri Mondor

    Créteil, France

  • CHU de Toulouse

    Toulouse, 31000, France

  • Hôpital Bretonneau

    Tours, France

  • Hôpital Claude Huriez

    Lille, France

  • Hôpital Saint-Antoine

    Paris, France

  • Hôpital de Hautepierre

    Strasbourg, France

  • Hôpital de Pontchaillou

    Rennes, France

  • University hospital of Toulouse

    Toulouse, 31000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.